Barrier Contraceptive Devices Three-Month Data OK For Approval, Panel Says
This article was originally published in The Gray Sheet
Three-month data is sufficient in demonstrating the efficacy of female barrier contraceptives in preventing pregnancy, a majority of FDA's Obstetrics and Gynecology Devices Panel agreed Oct. 4.
You may also be interested in...
YAMA'S LEA'S SHIELD FEMALE BARRIER CONTRACEPTIVE NEEDS 200-PATIENT STUDY, FDA PANEL FINDS; EXISTING DATA INSUFFICIENT TO ESTABLISH PREGNANCY RATE
Yama's Lea's Shield silicone vaginal barrier contraceptive device should be evaluated in a study of at least 200 subjects, FDA's Obstetrics and Gynecology Devices Panel concluded at its Oct. 21 meeting in Rockville, Maryland.
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.